Natalizumab: differenze tra le versioni

Versione delle 11:16, 8 apr 2019

Versione delle 07:23, 3 mag 2019

Riga 21:

== Bibliografia ==

*Piraino PS et al: ''Spontaneous remyelination following prolonged inhibition of alpha4 integrin in chronic EAE. ''J Neuroimmunol. 2005 Oct;167(1-2):53-63.Clicca [httphttps://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16095724&query_hl=7&itool=pubmed_docsum qui] per leggere

*Yednock TA et al: ''Alpha 4 beta 1 integrin-dependent cell adhesion is regulated by a low affinity receptor pool that is conformationally responsive to ligand.''J Biol Chem. 1995 Dec 1;270(48):28740-50. Clicca [httphttps://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7499396&query_hl=11&itool=pubmed_docsum qui] per leggere

*Kleinschmidt-DeMasters BK et al: ''Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis''. N Engl J Med. 2005 Jul 28;353(4):369-74. Epub 2005 Jun 9. Clicca [httphttps://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15947079&query_hl=21&itool=pubmed_docsum qui] per leggere

*Maguire JE et al: ''T cell receptor- and beta 1 integrin-mediated signals synergize to induce tyrosine phosphorylation of focal adhesion kinase (pp125FAK) in human T cells.'' J Exp Med. 1995 Dec 1;182(6):2079-90. Clicca [httphttps://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7500053&query_hl=13&itool=pubmed_docsum qui] per leggere

*Niino M et al: ''Natalizumab effects on immune cell responses in multiple sclerosis.'' Ann Neurol. 2006 May;59(5):748-54. Clicca [httphttps://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16634035&query_hl=15&itool=pubmed_docsum qui] per leggere

*Sheremata WA et al: ''A safety and pharmacokinetic study of intravenous natalizumab in patients with MS.'' Neurology. 1999 Mar 23;52(5):1072-4 Clicca [httphttps://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10102433&query_hl=17&itool=pubmed_docsum qui] per leggere

*MacDonald JK et al: ''Natalizumab for induction of remission in Crohn's disease''. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD006097. Clicca [httphttps://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17253580&query_hl=19&itool=pubmed_docsum qui] per leggere.

*Yousry TA et al: ''Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. ''N Engl J Med. 2006 Mar 2;354(9):924-33. Clicca [httphttps://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16510746&query_hl=28&itool=pubmed_docsum qui] per leggere.

== Collegamenti esterni ==